July 21, 2026 Danaher Corporation Reports Strong Q2 2026 Results Danaher Corporation reported significant Q2 2026 financial growth, including 60% increase in net earnings and raised guidance for full-year adjusted earnings. The strong performance reflects effective strategic initiatives and robust order trends in the Life Sciences segment.
July 21, 2026 Danaher Corporation Reports Strong Q2 2026 Results Amid Strategic Growth Initiatives Danaher Corporation reported a 5.5% revenue increase in Q2 2026, driven by strategic acquisitions and strong performance in Biotechnology and Life Sciences. Net earnings surged to $870 million, reflecting operational efficiencies and a successful acquisition of Masimo Corporation.
June 29, 2026 Danaher Foundation Pledges $1 Million for Ebola Relief Efforts On June 29, 2026, the Danaher Foundation committed $1 million to aid Ebola relief efforts in Central Africa, partnering with Save the Children, IRC, and WFP. This funding focuses on infection prevention, hygiene, health services, and food assistance to tackle the outbreak effectively.
June 22, 2026 Masimo Receives FDA Clearance for AI-Enabled Respiratory Monitoring Masimo has secured FDA clearance for its AI-enabled opioid-induced respiratory depression (OIRD) detection in the Radius VSM monitor. This innovative feature utilizes advanced algorithms for early respiratory risk detection, enhancing patient safety during opioid therapy.
June 22, 2026 Danaher Corporation Schedules Second Quarter 2026 Earnings Conference Call Danaher Corporation will host its Q2 2026 earnings conference call on July 21 at 8 AM ET. Investors can join via webcast or phone, with a replay available afterward. The call will provide insights into the company's financial performance and strategic direction.
June 10, 2026 Danaher Corporation Completes Acquisition of Masimo Corporation Danaher Corporation has successfully acquired Masimo Corporation, strengthening its diagnostics portfolio with advanced technology in patient monitoring. This strategic acquisition is expected to foster growth and innovation while Masimo remains a standalone entity within Danaher's operations.
June 01, 2026 Danaher Corp's SCIEX Launches Major Advancements to ZenoTOF Line SCIEX has announced significant upgrades to its ZenoTOF line, including the launch of SCIEX OS 5.0, designed to enhance research workflows. Key features include AI tools and enhanced data acquisition technologies, positioning SCIEX as a leader in mass spectrometry innovation.
June 01, 2026 Danaher Corporation Unveils SCIEX novus V55 System: A Leap Forward in Mass Spectrometry Danaher Corporation's SCIEX launched the novus V55 system, a next-gen mass spectrometer featuring enhanced sensitivity and operational efficiency. Key innovations include accelerated MRM capabilities, advanced software, and a compact design, addressing the needs of modern analytical laboratories.
May 06, 2026 Danaher Corporation to Showcase Innovations at Bank of America Securities Healthcare Conference Danaher Corporation will present at the Bank of America Securities Healthcare Conference on May 13, 2026, showcasing its commitment to healthcare innovation. CEO Rainer M. Blair will discuss the company's advancements and strategic vision aimed at improving patient care and sustainability.
May 05, 2026 Danaher Corporation Declares Quarterly Dividend Amidst Continued Growth Danaher Corporation has declared a quarterly cash dividend of $0.40 per share, set for payment on July 31, 2026. This move reflects the company's strong financial health and commitment to shareholder returns while pursuing growth in life sciences and diagnostics.
April 22, 2026 Danaher Corp Announces Pricing of Euro-Denominated Senior Notes Offering On April 22, 2026, Danaher Corporation announced a €3 billion euro-denominated senior notes offering aimed at funding its acquisition of Masimo Corporation. The offering includes various notes due between 2028 and 2038, with proceeds expected to enhance Danaher's capabilities in the life sciences sector.
April 21, 2026 Danaher Corporation Reports Strong First Quarter Results for 2026 Danaher Corporation reported strong Q1 2026 results with $1 billion in net earnings and a 3.5% revenue growth. The company is optimistic about future growth, driven by strategic initiatives and an upcoming acquisition of Masimo Corporation.
April 21, 2026 Danaher Corporation Reports Q1 2026 Financial Results: A Steady Growth Path Amid Challenges Danaher Corporation reported a 3.5% revenue increase in Q1 2026, led by growth in its Biotechnology and Life Sciences segments. Despite challenges in Diagnostics, the company maintains a strong financial position and actively pursues strategic acquisitions to enhance its market presence.
March 20, 2026 Danaher Corporation Announces First Quarter 2026 Earnings Conference Call Danaher Corporation has announced its Q1 2026 earnings conference call set for April 21, 2026, at 8:00 a.m. ET. The call will provide insights into the company’s financial health and strategic plans, with access available via webcast and telephone participation.
February 24, 2026 Danaher Corporation Declares Quarterly Dividend Amid Continued Commitment to Innovation Danaher Corporation has approved a quarterly dividend of $0.40 per share, payable on April 24, 2026. This decision highlights the company's robust financial position and dedication to shareholder value while continuing its commitment to health innovation.
February 24, 2026 Danaher Corporation to Present at TD Cowen Health Care Conference Danaher Corporation's CEO, Rainer M. Blair, will present at the TD Cowen Healthcare Conference on March 3, 2025. The event will highlight Danaher's commitment to innovation in life sciences and diagnostics, including insights on future strategies and advancements.
February 24, 2026 Danaher Corporation Reports 2025 Annual Results: A Mixed Landscape of Growth and Challenges Danaher Corporation's 2025 annual report reveals a 3.0% increase in revenue to $24.56 billion, driven by strong Biotechnology and Diagnostics performance. Despite facing regulatory challenges and a decline in net earnings, the company remains resilient with strategic investments for future growth.
February 17, 2026 Danaher Corporation Announces Acquisition of Masimo Corporation Danaher Corporation has announced its acquisition of Masimo Corporation for $9.9 billion, aiming to strengthen its diagnostics sector. The deal is expected to enhance patient monitoring solutions and generate significant synergies by 2027.
January 28, 2026 Danaher Corporation Reports Strong Fourth Quarter and Full-Year 2025 Results Danaher Corporation reported strong financial results for Q4 and the full year of 2025, with net earnings of $1.2 billion and $3.6 billion respectively. The company highlights innovation in its product offerings, driving growth in life sciences and diagnostics, and anticipates continued revenue increases into 2026.
January 12, 2026 Danaher Corporation Poised for Growth in 2026: Insights from Upcoming CEO Presentation Danaher Corporation is poised for growth in 2026, with projected mid-single digit revenue increases for Q4 2025. CEO Rainer M. Blair emphasizes the company's operational excellence and strategic advantages in the life sciences and diagnostics sectors.
January 05, 2026 Danaher Corporation to Present at J.P. Morgan Healthcare Conference Danaher Corporation will present at the J.P. Morgan Healthcare Conference on January 13, 2026, led by CEO Rainer M. Blair. The event will showcase Danaher's commitment to innovation in life sciences and diagnostics, emphasizing their role in advancing global health.
December 17, 2025 Danaher Corporation Schedules Fourth Quarter 2025 Earnings Conference Call Danaher Corporation is set to hold its fourth quarter earnings conference call on January 28, 2026, providing key financial insights. Participants can join via webcast or by phone, with replay options available shortly after the call.
December 09, 2025 Danaher Corporation Declares Quarterly Dividend Amidst Continued Innovation in Life Sciences Danaher Corporation has declared a quarterly cash dividend of $0.32 per share, scheduled for January 30, 2026. This decision highlights the company's strong financial position and ongoing commitment to innovation in healthcare, enhancing human health globally.
November 11, 2025 Danaher Corporation to Showcase Innovations at Jefferies Global Healthcare Conference Danaher Corporation will present its innovative healthcare solutions at the Jefferies Global Healthcare Conference on November 18, 2025. The event highlights Danaher's commitment to improving health outcomes through advanced technologies and collaborative approaches.
October 30, 2025 Investigation Launched into Danaher Corporation's Management Practices The Rosen Law Firm has launched an investigation into Danaher Corporation for potential breaches of fiduciary duties by its management. This raises significant concerns about the company's governance practices and may impact investor sentiment and stock performance. Shareholders are urged to stay informed as the situation develops.
October 24, 2025 Danaher Corporation Under Scrutiny: Shareholders Urged to Engage Danaher Corporation is under investigation for potential fiduciary breaches by its officers. Shareholders are encouraged to engage in governance reforms and explore options for redress to enhance transparency and accountability.
October 21, 2025 Danaher Corporation Reports Strong Third Quarter Results for 2025 Danaher Corporation's Q3 2025 results show a notable performance with net earnings of $908 million and revenues of $6.1 billion, driven by its innovative solutions. The company remains focused on delivering value and maintaining growth in the competitive healthcare landscape.
October 21, 2025 Danaher Corporation's Q3 2025 Report: A Mixed Bag of Growth and Challenges Danaher Corporation's Q3 2025 report shows a 4.5% revenue increase, driven by Biotechnology and Diagnostics segments, despite challenges in Life Sciences. The company faces mixed geographic performance and aims to enhance innovation for future growth.
September 26, 2025 Danaher Corporation Under Investigation: A Deep Dive into Recent Developments Danaher Corporation is under investigation following disappointing revenue disclosures and a securities class action lawsuit. The inquiry, led by Kahn Swick & Foti, LLC, examines potential breaches of fiduciary duties and compliance failures, raising concerns for shareholders about the company's governance and future prospects.
September 23, 2025 Danaher Corporation Schedules Third Quarter 2025 Earnings Conference Call Danaher Corporation has scheduled its Q3 2025 earnings conference call for October 21, 2025, at 8:00 a.m. ET. Investors can access the call via webcast and will receive insights into the company's financial performance and future expectations.
September 09, 2025 Danaher Corporation Declares Quarterly Dividend for Shareholders Danaher Corporation has declared a quarterly cash dividend of $0.32 per share, payable on October 31, 2025. This decision reflects the company's strong financial health and commitment to enhancing shareholder value within the competitive life sciences sector.
July 31, 2025 Danaher Corporation Welcomes Jonathan Leiken as New General Counsel Danaher Corporation has appointed Jonathan Leiken as General Counsel, succeeding Brian Ellis. Leiken, with extensive legal experience, will support Danaher's mission in the evolving life sciences sector.
July 22, 2025 Danaher Corporation Announces CFO Transition Plan Danaher Corporation has announced that Matthew Gugino will succeed Matthew McGrew as CFO effective February 28, 2026. McGrew will remain as Executive VP, ensuring a smooth transition as the company continues its mission in the life sciences sector.
July 22, 2025 Danaher Corporation Reports Q2 2025 Results: A Mixed Bag of Performance Danaher Corporation's Q2 2025 results show a 3.5% revenue increase, driven by strong Biotechnology and Diagnostics segments, despite challenges in Life Sciences. The company is focused on strategic acquisitions and operational adjustments to enhance profitability and navigate market dynamics.
July 22, 2025 Danaher Reports Strong Q2 2025 Results: A Closer Look Danaher Corporation's Q2 2025 results show a net earnings increase to $555 million, with revenue growth of 3.5%. The company is optimistic about maintaining momentum and achieving future growth.
June 27, 2025 Danaher Corp Appoints Greg Milosevich as Executive Vice President of Life Sciences Danaher Corporation has appointed Greg Milosevich as the new Executive Vice President of Life Sciences, effective July 1, 2025. With over a decade at Danaher, Milosevich's leadership is expected to enhance the company's commitment to innovation and customer satisfaction in the life sciences field.
June 27, 2025 Danaher Corporation Appoints Martin Stumpe as Chief Technology and AI Officer Danaher Corporation has appointed Martin Stumpe as Chief Technology and AI Officer, effective October 1, 2025. With extensive experience in AI and technology, Stumpe aims to enhance Danaher's digital transformation and innovation in healthcare, reporting directly to CEO Rainer Blair.
June 17, 2025 Danaher Corporation Schedules Second Quarter 2025 Earnings Conference Call Danaher Corporation has scheduled its second quarter 2025 earnings conference call for July 22. The call will provide insights into financial performance and future strategies, accessible via webcast and dial-in. A replay will be available post-call.
May 29, 2025 Danaher Corporation Partners with AstraZeneca to Enhance Precision Medicine Diagnostics Danaher Corporation has partnered with AstraZeneca to develop advanced diagnostic tools that enhance precision medicine. This collaboration aims to improve patient identification for targeted therapies, leveraging innovative technologies from Danaher's subsidiaries like Leica Biosystems.
May 15, 2025 Danaher Corporation Achieves Milestone in Personalized Medicine with mRNA-based CRISPR Therapy Danaher Corporation's subsidiaries Aldevron and IDT have achieved a milestone by producing the world's first personalized CRISPR gene editing therapy in just six months. This groundbreaking mRNA-based treatment aims to address urea cycle disorder in infants, showcasing rapid advancements in gene therapy and collaboration between industry and academia.
May 07, 2025 Danaher Corporation to Showcase Innovations at Bank of America Securities Healthcare Conference Danaher Corporation's CEO, Rainer M. Blair, will present at the Bank of America Securities Healthcare Conference on May 15, 2025. The presentation will focus on Danaher’s innovations in health technology and their impact on the healthcare landscape. A live webcast will be available for those unable to attend.
May 06, 2025 Danaher Corporation Declares Quarterly Dividend Amidst Strong Market Position Danaher Corporation has declared a quarterly cash dividend of $0.32 per share, payable on July 25, 2025. This decision reflects the company's strong financial health and commitment to innovation in the life sciences and diagnostics sectors.
April 22, 2025 Danaher Corporation Reports First Quarter 2025 Results Danaher Corporation reported strong Q1 2025 results with net earnings of $1.0 billion despite a 1% revenue decline. The company anticipates low-single-digit growth for Q2 and a solid outlook for the full year, leveraging its strengths in bioprocessing and diagnostics.
March 20, 2025 Danaher Corporation Schedules First Quarter 2025 Earnings Conference Call Danaher Corporation has scheduled its Q1 2025 earnings conference call for April 22, 2025. Investors can access the call via webcast and will receive insights into the company's financial performance and strategic direction.
March 13, 2025 SWOT Analysis of Danaher Corporation in 2025 This article analyzes Danaher Corporation's strategic position for 2025, detailing its strengths in market leadership and innovation, weaknesses like economic vulnerability, opportunities in emerging markets, and threats from competition and regulatory changes.
February 25, 2025 Danaher Corporation to Present at TD Cowen Healthcare Conference Danaher Corporation will be represented by CEO Rainer M. Blair at the TD Cowen Healthcare Conference on March 5, 2025. The event emphasizes Danaher's commitment to health innovation and will be accessible via a live webcast, showcasing the company's strategic vision and contributions to the healthcare sector.
February 20, 2025 Danaher Corporation Strengthens Board with Appointment of Charles Lamanna Danaher Corporation has appointed Charles Lamanna to its Board of Directors, enhancing its focus on artificial intelligence and technology. Lamanna's extensive experience at Microsoft and in AI development aligns with Danaher's mission to improve human health through innovation.
February 20, 2025 Danaher Corp's 2024 Annual Report: A Year of Challenges and Adaptation Danaher Corporation's 2024 annual report reveals flat revenues of $23.87 billion amid macroeconomic challenges. The company navigated declines in core sales, particularly in Biotechnology, while focusing on strategic acquisitions and operational excellence for future growth.
February 20, 2025 Danaher Corporation Announces Substantial Increase in Quarterly Dividend Danaher Corporation has announced an 18.5% increase in its quarterly cash dividend to $0.32 per share, demonstrating its solid financial position and commitment to shareholders. This increase underscores Danaher’s focus on innovation in the life sciences and diagnostics sectors, aiming for long-term growth.
October 22, 2024 Danaher Corp: Q3 2024 Financial Report Highlights Resilience Amid Challenges Danaher Corporation's Q3 2024 financial report reveals a 3% increase in revenues, driven by the Diagnostics segment, despite challenges in net income and operating margins. The company continues to pursue strategic acquisitions and innovation to navigate a competitive market landscape.
July 23, 2024 Danaher Corporation Reports Q2 2024 Results: Navigating Challenges in a Dynamic Market Danaher Corporation reported a 3% revenue decline in Q2 2024, yet maintained strong operating profit margins. Despite challenges in biotechnology and life sciences, growth in diagnostics and strategic acquisitions suggest potential for recovery.
April 23, 2024 Danaher Corp. Reports Q1 2024 Financial Results Danaher Corp's Q1 2024 financial results show a 2.5% revenue decline, driven by challenges in the Biotechnology segment. Despite this, the Diagnostics segment grew by 6.5%, reflecting mixed performance across business areas. The company remains focused on innovation and operational efficiency.
